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We assessed the impact of 2% daily patient bathing 
with chlorhexidine gluconate (CHG) washcloths on the 
incidence of hospital-acquired (HA) and central line-
associated (CLA) bloodstream infections (BSI) in inten-
sive care units (ICUs). We searched randomised studies 
in Medline, EMBASE, Cochrane Library (CENTRAL) and 
Web of Science databases up to April 2015. Primary 
outcomes were total HABSI, central line, and non-
central line-associated BSI rates per patient-days. 
Secondary outcomes included Gram-negative and 
Gram-positive BSI rates and adverse events. Four ran-
domised crossover trials involved 25 ICUs and 22,850 
patients. Meta-analysis identified a total HABSI rate 
reduction (odds ratio (OR): 0.74; 95% confidence 
interval (CI): 0.60–0.90; p = 0.002) with moderate 
heterogeneity (I2 = 36%). Subgroup analysis identi-
fied significantly stronger rate reductions (p = 0.01) for 
CLABSI (OR: 0.50; 95% CI: 0.35–0.71; p < 0.001) than 
other HABSI (OR: 0.82; 95% CI: 0.70–0.97; p = 0.02) 
with low heterogeneity (I2 = 0%). This effect was evi-
dent in the Gram-positive subgroup (OR: 0.55; 95% CI: 
0.31–0.99; p = 0.05), but became non-significant after 
removal of a high-risk-of-bias study. Sensitivity analy-
sis revealed that the intervention effect remained sig-
nificant for total and central line-associated HABSI. We 
suggest that use of CHG washcloths prevents HABSI 
and CLABSI in ICUs, possibly due to the reduction in 
Gram-positive skin commensals.
Introduction
Hospital-acquired bloodstream infections (HABSI) and 
the subgroup of central line-associated bloodstream 
infections (CLABSI) are associated with substantial 
morbidity, mortality, and healthcare costs in adults and 
children [1-5], with higher infection rates among hospi-
talised children [6]. Data from the EPIC II study have 
shown that of all nosocomial infections in the inten-
sive care unit (ICU), 15% were bloodstream infections 
(BSI), with CLABSI accounting for 4.7% [7,8]. Due to the 
substantial impact on patient outcomes and their pre-
ventable nature, reduction of HABSI is the emphasis of 
several patient safety initiatives [9-11].
CLABSI results from catheter tip contamination by com-
mensal skin flora at time of device insertion and later 
from microorganisms migrating from skin to the cathe-
ter tip or lumen [12]. The risk of CLABSI can be reduced 
by antiseptic skin preparation immediately before 
catheter insertion and by maintaining asepsis at inser-
tion site and catheter access points [13]. As a substan-
tial proportion of primary BSI originate from vascular 
access devices, these infections also decrease follow-
ing preventive interventions targeting CLABSI [14].
Chlorhexidine gluconate (CHG) has broad antimicrobial 
action, prolonged residual effect, and is the agent of 
choice for skin disinfection before catheter insertion 
[13,15,16]. CHG can also be used in basic hygienic care 
as a liquid bathing agent or as pre-packaged CHG-
impregnated washcloths [17].
A substantial number of studies investigated the value 
of CHG washcloth patient bathing. Three recent sys-
tematic reviews summarised the available evidence 
concerning colonisation and infection rates [18-20]. 
Low-quality, non-randomised studies demonstrated 
mixed effects for prevention of BSI. The effect of 
CHG-impregnated washcloths on hard outcomes such 
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as rates of HABSI and CLABSI in both adult and pae-
diatric ICU patients remains unclear. We performed a 
systematic review and meta-analysis of randomised-
controlled trials to assess the impact of daily care with 
CHG washcloths on rates of total HABSI and CLABSI 
in adult and paediatric ICU patients. Subgroup analy-
sis identified the impact on Gram-positive and Gram-
negative microorganisms.
Methods
Search strategy
The Medline, EMBASE, Cochrane Library and Web of 
Science databases were systematically searched using 
combinations of the key terms ‘chlorhexidine’, ‘chlo-
rhexidine impregnated washcloths’, ‘neonatal’, ‘pae-
diatric’ ‘intensive care unit’, ‘bloodstream infection’, 
‘catheter related infection’ and ‘randomised controlled 
trial’ (Box 1-2, Figure 1). The search strategy included 
publications until end of April 2015. No predefined 
review protocol was registered.
Study selection
Eligible studies included randomised trials done in 
adult, paediatric and neonatal ICUs that compared 
the impact of daily bathing with CHG washcloths with 
that of non-antiseptic impregnated washcloths or 
other standard bathing procedures on HABSI rates. 
Languages were restricted to English, French, Dutch 
and Portuguese. The primary outcome measure was 
number of HABSIs per patient-days. One reviewer per-
formed study selection and consensus was achieved 
between two reviewers. Search results were screened 
by title and abstract. Selected papers underwent a full-
text assessment and eligibility issues were resolved 
between reviewers (EA, KB, SB).
Data extraction and quality assessment
Extracted data included study setting, design and sam-
ple size, implemented interventions, definitions and 
primary outcome data on rates of CLABSI and HABSI 
per patient-days in the treatment and control groups 
from the intention-to-treat populations. Data were man-
ually calculated when necessary. Secondary outcome 
measures included Gram-positive and Gram-negative 
aetiology, study-related adverse events and number 
of catheter-days and patients. When available, the 
protocols were examined for discrepancies between 
original study objectives and the published data. Two 
independent reviewers performed data extraction and 
independently assessed the methodological quality 
of included studies using the Cochrane risk-of-bias 
assessment tool (EA, KB) [21].
Statistical analysis
A random-effects meta-analysis using the inverse vari-
ance method obtained odds ratios (OR) and 95% con-
fidence intervals (CI) for total HABSI rates per 1,000 
patient-days. A random-effects model was chosen to 
encompass clinical heterogeneity in baseline stand-
ards of care between ICUs. Heterogeneity was prede-
fined and assessed through the I2 test (I2 ≤ 25% for 
low, 25% < I2 < 50% for moderate and I2 ≥ 50% for high). 
Predefined subgroup analysis and meta-regression 
were performed on HABSI subtype (CLABSI and non-
central line HABSI) and pathogen subtype (Gram-
negative and Gram-positive). Sensitivity analysis 
assessed the impact of varying incidence rate denomi-
nator data (number of catheter-days and patients) 
and the removal of studies with a high risk of bias. 
Assessment of publication bias by funnel plot was 
planned when considered meaningful (i.e. at least 10 
studies included). Review Manager version 5.2.0 was 
used for meta-analysis models and Comprehensive 
Meta Analysis version 2.0 was used to perform meta-
regression. A p value ≤ 0.05 was considered statistically 
significant.
Results
The search strategy yielded 291 records. Following title, 
abstract and full-text assessment, four papers were 
included for meta-analysis (Figure 2) [22-25], and one 
study was excluded because it had an inappropriate 
Box 1
Systematic Review Protocol
Inclusion criteria
• Randomised controlled trials
• Adult ICU population
• Paediatric ICU population
• Neonatal ICU population
• Intervention arm including patient bathing with CHG 
washcloths
• Control arm including other standard bathing procedures 
(not with CHG or other antiseptic)
• Records investigating impact of intervention in HABSI and 
CLABSI
• Full text available
Exclusion criteria
• Descriptive studies
• Before-and-after design
• Evidence of confounders such as other interventions 
implemented at the same time as CHG washcloth bathing 
(i.e. care bundles)
• Comparative studies
• Reviews, systematic reviews and meta-analysis
• Studies that did not use CHG in the form of washcloths
CHG: chlorhexidine gluconate; CLABSI: central line-associated 
bloodstream infection; HABSI: hospital-acquired bloodstream 
infection; ICU: intensive care unit.
3www.eurosurveillance.org
1. MEDLINE search (181 titles found, 7 without accessible full text, 159 excluded, 18 duplicates, 4 eligible studies)
• Chlorhexidine impregnated washcloths AND catheter related bloodstream infection
• Chlorhexidine impregnated washcloths AND bloodstream infection
• Chlorhexidine[MeSH Terms] AND infection transmission[MeSH Terms] AND care units, intensive[MeSH Terms]
• Chlorhexidine[MeSH Terms] AND bath[MeSH Terms] AND pediatric intensive care units[MeSH Terms]
• Chlorhexidine[MeSH Terms] AND bath[MeSH Terms] AND intensive care unit[MeSH Terms]
• Chlorhexidine[MeSH Terms] AND care, neonatal intensive[MeSH Terms]
• Chlorhexidine[MeSH Terms] AND care unit, intensive[MeSH Terms] AND catheter related infection[MeSH Terms]
• Chlorhexidine wash[MeSH Terms] AND BSI
• Chlorhexidine impregnated AND CLABSI
• Chlorhexidine impregnated AND BSI
• Chlorhexidine impregnated AND Pediatric
• Chlorhexidine impregnated AND Neonatal
• Randomized controlled trial[Publication Type]) AND ICU AND Chlorhexidine
• Randomized controlled trial[Publication Type] AND intensive care unit) AND chlorhexidine impregnated
• Chlorhexidine[MeSH Major Topic] AND randomized controlled trial[Publication Type] AND ICU
2. EMBASE search (14 titles found, 12 excluded, 2 duplicates)
• Bath/ and *chlorhexidine gluconate/ and intensive care unit/
• Chlorhexidine washcloths and intensive care unit).af
• Chlorhexidine washcloths and neonatal).af
• Randomized controlled trial.pt. and chlorhexidine washcloths.af
• 3 Web of Science search (81 studies found, 78 excluded, 3 duplicates)
• TS=(chlorhexidine AND wash*) AND TS=(intensive care unit)
• TS=(chlorhexidine AND wash*) AND TS=(pediatric)
• TS=(chlorhexidine AND wash*) AND TS=(neonatal intensive care)
• TS=(chlorhexidine AND wash*) AND TS=(BSI)
• TS=(chlorhexidine AND wash*) AND TS=(CLABSI)
• 4. Cochrane Library search (15 titles found, 7 excluded, 8 duplicates)
• ‘Randomized* in Publication Type AND chlorhexidine wash* AND “intensive care unit” NOT “oral”NOT “hand” in Trials’
• ‘Randomized* in Publication Type and chlorhexidine bath* and Intensive Care Unit in Trials’
• ‘Randomized* in Publication Type and chlorhexidine bath* and “intensive care unit” and “neonatal” in Trials’
• ‘Randomized* in Publication Type and chlorhexidine bath* and “intensive care unit” and “BSI” in Trials’
• ‘Randomized* in Publication Type and chlorhexidine washcloth and “intensive care unit” in Trials’
BSI: bloodstream infection; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired bloodstream infection; 
ICU: intensive care unit.
Box 2
Search terms used for study selection
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non-randomised study design. The included studies 
were non-blinded cluster-randomised crossover tri-
als involving, together, 22,850 patients from 15 adult 
and 10 paediatric ICUs (Table 1). The treatment group 
included daily patient bathing with 2% CHG wash-
cloths. Control groups applied daily bathing with 
non-antiseptic impregnated washcloths or other non-
medicated standard bathing procedures in ICUs with 
comparable baseline infection rates.
The four included studies compared daily 2% CHG 
washcloth patient bathing with a control arm applying 
washcloths not impregnated with CHG: non-medicated 
washcloths [22,23], soap and water [24] or not further 
specified non-medicated standard bathing procedures 
[25]. Climo et al. performed their study in nine medi-
cal adult ICUs and bone marrow transplantation units 
[22] and Bleasdale et al. performed a single-centre 
study in a medical ICU [24]. Milstone et al. studied the 
intervention impact in 10 paediatric ICUs [25]. Noto et 
al. selected five adult ICUs in the same institution (car-
diac, trauma, neurological, medical and surgical) [23]. 
Total HABSI rates in the control arm were comparable 
between the three multicenter studies (5.5–6.6 HABSI 
per 1,000 patient-days) [22,23,25], with one study 
reporting twice larger infection rates (12.2 HABSI per 
1,000 patient days) in a single ICU [24]. The rates of 
CLABSI in the control arm varied per study between 
0.19 [23], 1.7 [22,25] and 9.9 CLABSI per 1,000 patient 
days [24].
All 25 units were randomly assigned to either a treat-
ment or a control group. Duration of study period was 
10 weeks [23], 6 months [22,25], and 6 or 7 months in 
both control and treatment groups [24]. Three of the 
four studies applied washout phases between control 
and treatment study periods, lasting two [23,24] or six 
weeks [25]. The study by Climo et al. did not include a 
washout phase between intervention and control study 
periods [22]. Three of the studies reported that nurses 
received training on how to perform bathing and how 
to identify adverse events related or unrelated to the 
treatment [22,24,25]. All four trials were non-blinded to 
patients, caregivers and staff.
Climo et al., Bleasdale et al. and Noto et al. included 
all admitted adult patients in the ICUs who agreed to 
participate except those with adverse skin conditions 
[22-24]. Eight patients refused to participate in the 
study by Climo et al. and were not included in the final 
analysis [22]. Bleasdale et al. excluded three patients 
who lacked skin integrity, declined participation or 
developed a skin rash. However, these patients were 
included in the final intention-to-treat analysis [24]. 
Milstone et al. used an intention-to-treat approach 
when selecting paediatric patients for analysis. All 
children admitted in the paediatric ICU were eligible 
for this study except those younger than two months, 
those with a present epidural or lumbar drain, skin dis-
ease, burns or CHG allergy or those without parental 
consent. The intention-to-treat population included all 
children older than two months with an informed con-
sent to participate, whereas the per-protocol popula-
tion included all the children who received treatment 
and were not excluded because of adverse reac-
tions [25]. Finally, Noto et al. stated that all admitted 
patients were randomised and patients admitted dur-
ing the washout periods were excluded [23].
Figure 1
Study selection according to online databases
ICU/BSI/
CLABSI
concept
RCT 
within ICU RCT
concept
Relevant 
records
CHG-WC
in ICU/BSI/
CLABSI
RCT with
CHG -WC
CHG-WC
concept
BSI: bloodstream infection; CHG-WC: chlorhexidine gluconate 
washcloth; CLABSI: central line-associated bloodstream infection; 
ICU: intensive care unit; RCT: randomised controlled trial.
Figure 2
Summary of literature search and study selection (n = 291)
291 records identified
31 duplicates removed
260 records screened by title/ abstract 
5 full articles assessed for eligibility 
4 articles included for meta-analysis 
255 records excluded
44 with inappropriate study design
16 used CHG non- washcloth bathing
29 included extra intervention
23 did not report infection rate
12 had inappropriate article type
131 where CHG was not used for bathing
1 full-text article excluded 
due to study design 
CHG: chlorhexidine gluconate.
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Climo et al. and Noto et al. defined primary HABSI as a 
BSI detected at least 48 hours after admission without 
an attributable secondary source of infection. Bleasdale 
et al. used the 1988 definitions from the United States 
Centers for Disease Control and Prevention (CDC) 
for nosocomial infections for HABSI and CLABSI [26]. 
These criteria require catheter cultures to define cen-
tral line bloodstream infections, as opposed to more 
recent CLABSI definitions of a HABSI occurring in in 
a patient with a central line (within 48 hours) with no 
other clear infectious source. Climo et al. and Noto et 
al. applied the CDC and National Healthcare Safety 
Network (NHSN) definitions for CLABSI and HABSI [27]. 
Noto et al. reported combined primary and second-
ary HABSI rates. Milstone et al. likewise applied CDC/
NHSN definitions, however they defined their blood-
stream infections by any single positive blood culture, 
including for commensal skin microorganisms [25]. The 
authors justified the adjusted definition criteria by 
stating that morbidity from bacteraemia is significant 
Figure 3
Meta-analysis of the impact of chlorhexidine gluconate washcloth bathing on total rate of hospital-acquired bloodstream 
infections per patient-days (n = 4 studies)
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CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; control: bathing with non-impregnated washcloths.
Figure 4
Subgroup analysis of rates of central line-associated bloodstream infection and non-central line-associated hospital-acquired 
bloodstream infection per patient days (n = 4 studies) 
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BSI: bloodstream infection; CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; CLABSI: central line-
associated bloodstream infection; control: bathing with non-impregnated washcloths.
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in critically ill children. Microorganisms identified as 
Gram-positive or Gram-negative were isolated from 
combined primary BSI and CLABSI [22,24,25] or from 
total HABSI [23].
Three studies evaluated study-related adverse events 
associated with the use of CHG washcloths [22,24,25], 
but none reported serious adverse events. Milstone et 
al. specified the occurrence of skin reactions in 69 (2%) 
patient admissions, with a greater percentage occurring 
in the treatment group than in the control group (n = 43 
(3%) vs n = 26 (1%); p < 0.0001). Only 28% (12/43) 
of these reactions were considered to be due to CHG 
washcloths. Crude incidence of CHG-related adverse 
events was 1.12 per 1,000 patient-days (95% CI: 0.06–
2.02) [25]. One study found a higher overall incidence 
of skin reactions in the control group (n = 130 (3.4%)) 
rather than the intervention arm (n = 78 (2%)), with all 
reactions considered not related to the CHG washcloth 
bathing intervention [22]. Bleasdale et al. reported 
three cases of skin reaction in the intervention group, 
which were likewise not attributed to CHG washcloth 
use [24]. The study by Noto et al. did not report any 
adverse events [23]. Only the study by Bleasdale et al. 
studied the minimum inhibitory concentration (MIC) for 
chlorhexidine resistance of microorganisms in the con-
trol and intervention arms, however neither the data 
nor significance values were reported.
Risk of bias assessment was performed using the 
Cochrane Collaboration tool for risk of bias assess-
ment (Table 2) [21]. Besides the inability to blind the 
intervention to patients and staff and the lack of com-
pliance measurements for interventions or baseline 
hygienic practices in all studies, the main confounder 
that introduced a high risk of bias was the simplified 
definition applied by Milstone et al. for their paediatric 
population. In that study, only one positive blood cul-
ture was required to diagnose a bloodstream infection, 
including commensal skin microorganisms. In the same 
vein, none of the included articles reported diagnostic 
methods of catheter or blood culturing. Other sources 
of bias included lack of a washout phase and no men-
tion of outcome assessment blinding in the Climo et al. 
study. Issues that confounded generalisability include 
higher HABSI rates in the Bleasdale et al. trial and 
lower HABSI rates and shorter mean length of stay in 
the Noto trial.
Meta-analysis was performed on the randomised 
crossover trials to assess the impact of CHG wash-
cloth bathing. A reduction in the rate of total HABSI 
was associated with CHG washcloth bathing (OR: 0.74; 
95% CI: 0.60–0.90; p = 0.002, Figure 3) with moderate 
statistical heterogeneity (I2 = 36%). One study did not 
demonstrate a rate reduction of total HABSI [23].
Figure 5
Subgroup analysis of rates of hospital-acquired Gram-positive and Gram-negative bloodstream infections per patient days 
(n = 4 studies)
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BSI: bloodstream infection; CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; control: bathing with non-
impregnated washcloths.
Noto et al. reported microorganism data on combined primary and secondary hospital-acquired bloodstream infection [23].
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In Climo et al.’s study, CLABSI rate was 53% lower in 
the CHG washcloth group than in the control group 
[22]. Bleasdale et al. described a lower CLABSI risk 
in the CHG washcloth group than in the control group 
[24]. Milstone et al.’s study on paediatric patients 
found a decreased incidence of BSI in patients with a 
central line (p = 0.03). However, CHG washcloth bath-
ing was not associated with a significantly decreased 
incidence of CLABSI (p = 0.08) [25]. Noto et al. did not 
report a significant impact of using CHG washcloths on 
the rates of CLABSI [23].
Subgroup analysis found a significant reduction in 
CLABSI (OR = 0.50; 95% CI: 0.35–0.71; p ≤ 0.001, Figure 
4) and non-central line-associated HABSI rates per 
1,000 patient days (OR = 0.82; 95% CI: 0.70–0.97; 
p = 0.02). Both subgroups displayed lower heteroge-
neity compared with the total HABSI rate reduction 
(I2 = 0%), demonstrating that heterogeneity between 
studies is partially explained by which infectious out-
come is being studied. The effect of CHG washcloth 
bathing was more pronounced for CLABSI prevention 
and the difference in impact was significant (p = 0.01). 
Three of the four studies reported the cultured micro-
organisms for combined primary and central line-asso-
ciated HABSI, while the Noto study reported data on 
combined primary and secondary HABSI [25]. Subgroup 
analysis found a significant decrease in Gram-positive 
(OR = 0.55; 95% CI: 0.31–0.99; p = 0.05) but not 
Gram-negative HABSI (OR = 0.83; 95% CI: 0.59–1.17; 
p = 0.68) (Figure 5). Meta-regression did not identify 
a significant difference between Gram-positive and 
Gram-negative subgroups.
A funnel plot was not created due to the small number of 
included studies. Sensitivity analysis compared meta-
analysis results for varying denominators per HABSI. 
The intervention effect per number of patients was 
comparable for total HABSI (OR = 0.73; 95% CI: 0.58–
0.91; p = 0.006), CLABSI (OR = 0.50; 95% CI: 0.35–0.71; 
p = 0.0001) and non-central line HABSI (OR = 0.82; 95% 
CI: 0.68–0.97; p = 0.02). Three trials demonstrated 
that the overall effect on CLABSI per catheter-days was 
similar (OR = 0.52; 95% CI: 0.36–0.74; p = 0.0003) with 
one study demonstrating a non-significant decrease 
[25]. The definitions of HABSI in the paediatric popula-
tion of Milstone et al. required only one blood culture, 
even in the case of skin commensals. After exclusion 
of this high-risk-of-bias study, meta-analysis identi-
fied a reduction of the total HABSI (OR = 0.76; 95% CI: 
0.59–0.99; p = 0.04) and CLABSI rate per patient days 
(OR = 0.50; 95% CI: 0.33–0.76; p = 0.02), and the rate 
reduction for non-central line HABSI, Gram-positive 
and Gram-negative HABSI became non-significant. The 
difference between CLABSI and non-central line HABSI 
remained significant after removal of this high-risk-of-
bias trial (p = 0.02).
Table 1
Summary of included studies (n = 4)
Study Setting Sample size
Intervention 
group
Control 
group
Primary 
outcome
Secondary 
outcome Results
Climo 
(2013) [ 
22 ] 
9 ICU and 
bone marrow 
transplant units
7,727 
patients
CHG-WC daily 
bathing
Daily bath 
with non-
medicated 
washcloths
Primary, 
secondary, 
and central 
line-
associated 
BSI
Primary HABSI 
and CLABSI 
microorganisms
Control: 88 primary HABSI, 43 
CLABSI, 34 secondary HABSI 
for 25,000 patient-days. 
Intervention: 69 primary 
HABSI, 21 CLABSI, 29 
secondary HABSI for 24,931 
patient days.
Noto (2015) 
[ 23 ] 
5 adult ICUs 
(neurological, 
trauma, surgical, 
medical, 
cardiovascular)
9,340 
patients
CHG-WC daily 
bathing
Non-
medicated 
washcloths
Combined 
primary and 
secondary 
HABSI, and 
CLABSI
Combined 
primary, 
secondary HABSI, 
and CLABSI 
microorganisms
Control: 113 primary and 
secondary HABSI, 4 CLABSI for 
20,721 patient-days. 
Intervention: 96 primary and 
secondary HABSI, 4 CLABSI for 
19,202 patient days.
Bleasdale 
(2007) [ 
24 ] 
1 medical ICU 836 patients
CHG-WC daily 
bathing
Soap and 
water 
bathing
Combined 
primary 
HABSI and 
CLABSI, and 
secondary 
HABSI
Combined primary 
HABSI and CLABSI 
microorganisms
Control: 21 CLABSI, 1 primary 
HABSI, 5 secondary HABSI for 
2,119 patient days. 
Intervention: 9 CLABSI, 0 
primary HABSI, 5 secondary 
HABSI for 2,210 patient days.
Milstone 
(2013) [ 25 ] 
10 paediatric 
ICUs
4,947 
patients
CHG-WC daily 
bathing
Either soap 
and water 
or non-
medicated 
washcloths
Combined 
primary and 
secondary 
HABSI, and 
CLABSI
Combined primary 
HABSI and CLABSI 
microorganisms
Control: 79 primary and 
secondary HABSI, 28 CLABSI 
for 16,024 patient days. 
Intervention: 53 primary and 
secondary HABSI, 13 CLABSI 
for 15,057 patient days.
ICU: intensive care unit; BSI: bloodstream infection; CHG-WC: 2% chlorhexidine gluconate washcloth; CLABSI: central line-associated 
bloodstream infection; HABSI: hospital-acquired bloodstream infection.
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Discussion
This meta-analysis of four trials, involving 25 ICUs and 
22,850 patients, provides evidence that daily patient 
bathing with CHG washcloths can reduce the inci-
dence of HABSI. This effect appears mainly to be due 
to a reduction in CLABSI, possibly based on eradica-
tion of Gram-positive skin commensals. After removal 
of a high-risk-of-bias study, the intervention impact 
in the Gram-positive and non-central line-associated 
HABSI subgroups became non-significant. No signifi-
cant adverse skin events were reported as related to 
CHG washcloth bathing. One study planned a cost-
effectiveness analysis per protocol, but did not report 
this in the final publication [22]. Among the four stud-
ies, significant reductions in individual infection rate 
were demonstrated for total HABSI (n = 3) and for the 
subgroups of Gram-positive HABSI (n = 3) and CLABSI 
(n = 3). The subgroup analysis of non-central line HABSI 
demonstrated rate reductions, however no single study 
could independently demonstrate significance. Only 
Noto et al consistently reported non-significant results: 
in contrast to the other included studies, their CLABSI 
rate did not change, with broad CIs [23]. A possible 
explanation could be the infection rate in the control 
group (0.19 CLABSI per 1,000 patient-days), which 
was at least 10 times lower compared with other tri-
als [22,25], and the mean length of stay of 2.5 days, 
approximately half that of the other included studies 
[22,24,25].
Table 2
Cochrane risk-of-bias assessment of included studies (n = 4)
Climo (2013) [22] Noto (2015) [23] Bleasdale (2007) [24] Milstone (2013) [25]
Random sequence 
generation 
and allocation 
concealment 
Investigators were unblinded 
to intervention assignment. 
No mention of blinding of 
outcome assessments.
Infection control personnel 
responsible for adjudicating 
infection outcomes were 
blinded to the treatment 
assignments.
One of three reviewers was 
blinded to intervention 
assignment. To avoid 
bias, infection rates were 
calculated with a computer 
algorithm on a data 
warehouse.
Investigators were 
unblinded to intervention 
assignment. Outcome 
assessors were masked to 
random allocations.
Selection bias Medium risk Low risk Low risk Low risk
Blinding of 
participants and 
personnel 
Due to the nature of the study, none of the studies could blind intervention to staff or patients.
Blinding of 
outcome 
assessment 
Investigators were unblinded 
to intervention assignment. 
No mention of blinding of 
outcome assessments.
Infection control personnel 
responsible for adjudicating 
infection outcomes were 
blinded to the treatment 
assignments.
Two reviewers were 
unblinded to intervention 
assignment; a third reviewer 
was blinded. To avoid 
bias, infection rates were 
electronically calculated 
using a computer algorithm 
on a data warehouse.
Investigators were 
unblinded to intervention 
assignment. Outcome 
assessors were masked to 
random allocations.
Performance bias Medium risk Low risk Low risk Low risk
Incomplete 
outcome data 
Reported cost-effectiveness 
outcomes did not coincide 
with the protocol. 
Adverse events reported. 
Chlorhexidine susceptibility 
testing was reported. No 
compliance reporting.
Reported primary and 
secondary outcomes 
coincided with the protocol. 
No data on chlorhexidine 
resistance. No compliance 
reporting.
Reported primary and 
secondary outcomes 
coincided with the protocol. 
Adverse events reported. 
Chlorhexidine susceptibility 
testing was reported. No 
compliance reporting.
Reported primary and 
secondary outcomes 
coincided with the 
protocol. Adverse events 
reported. No data on 
chlorhexidine resistance. 
No compliance reporting.
Detection bias Low risk Low risk Low risk Low risk
Selective reporting 
Cost-effectiveness data not 
mentioned in the study report 
but mentioned in the study 
protocol. Only intention-to-
treat group reported.
Intention-to-treat and 
as-treated group analysis 
provided. Adverse events 
not reported.
Only an intention-to-treat 
analysis was performed. 
Three patients excluded 
from the CHG bathing 
procedure were considered 
part of the intervention arm.
Per protocol and intention-
to-treat group analysis 
provided.
Attrition bias Low risk Low risk Low risk Low risk
Other sources of 
bias 
Sage Products supplied the 
washcloths, technical and 
educational support, but 
was not involved in the study 
design, analysis or manuscript 
preparation.
Single-centre study with 
lower baseline HABSI 
rates and length of stay 
compared with other 
included studies.
Single-centre study with 
higher baseline CLABSI 
rates compared with other 
studies.
Different institutions’ 
ethics committees decided 
how to obtain informed 
consent. BSI criteria 
required only one blood 
culture for commensal 
microorganisms.
Other bias Low risk High risk Medium risk High risk
BSI: bloodstream infection; CHG: chlorhexidine gluconate; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired 
bloodstream infection.
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Two previous systematic reviews had found evidence 
of the preventive effect of CHG washcloth bathing for 
CLABSI [18] and HABSI [20]. Another could not con-
clude that CHG washcloth bathing could reduce BSI 
rates [19]. However, the majority of included studies 
were low-quality non-randomised before–after stud-
ies, did not focus solely on ICU patients, and applied 
different CHG bathing interventions. In contrast, this 
review focused on non-rinse CHG washcloth bathing to 
prevent HABSI in ICUs, including pediatric ICUs.
Strengths of this meta-analysis comprise the com-
prehensive search strategy, inclusion of high-quality 
randomised crossover trials, risk-of-bias assessment, 
random-effects meta-analysis with subgroup analysis 
of HABSI and pathogen subtypes, low statistical het-
erogeneity in the HABSI types subgroup analysis and 
sensitivity analysis of high-risk-of-bias studies and 
denominator data. Limitations include non-blinding to 
the intervention, partially compensated by the cross-
over design, lack of compliance measurements and 
lack of reporting of baseline hygienic practices. Since 
all four included trials were carried out in critically 
ill patients with a high level of dependency on staff, 
patient self-reporting of compliance and tolerance was 
not performed. One trial did not report blinding of out-
come assessment and lacked a washout period [22] 
and another was single-centre, even though it included 
two geographically distinct units that permitted a ran-
domised crossover design [24].
Clinical and methodological heterogeneity stemmed 
from differing infection rates, varying methods of 
reporting HABSI types and definition criteria of HABSI 
in the paediatric study. Different baseline standards 
of care leave more or less room for improvement and 
HABSI prevention, which can influence the perceived 
effect of the CHG washcloth intervention. The Bleasdale 
study had higher rates of HABSI in the control arm and 
the Climo study higher rates of CLABSI, compared with 
other hospital settings. This could have produced inter-
pretation and applicability bias in that a situation with 
more room for improvement in healthcare quality may 
predispose the infection rate reduction to be stronger 
[24]. Nevertheless, in the subgroup analysis of cen-
tral line and non-central line HABSI, the heterogeneity 
between studies decreased (I2 = 0%), indicating that 
the intervention effect was related to a proportional 
decrease in HABSI of central line or non-central line 
origin. An important source of methodological hetero-
geneity was the Milstone study due to their definition 
of bacteraemia as one, instead of two, positive blood 
culture of commensal skin organisms [25]. According 
to the current evidence, commensal Gram-positive 
bacteria cause a large proportion of BSI in children; 
however, they frequently contaminate blood cultures 
[28,29]. This change in HABSI definition means that 
the observed intervention effect may represent a false 
reduction in the yield of contaminated blood cultures 
that was due to a decrease in commensal skin flora 
and not to a reduction in bloodstream infections. After 
removal of this high-risk-of-bias study, a significant 
reduction was still maintained for total HABSI rates 
and particularly for the CLABSI subgroup.
The main purpose of patient safety strategies should 
be to improve quality of care by reducing the clinical 
and economic burden of healthcare-associated infec-
tions. Studies performed in the pre-surgical context 
have proven the cost-effectiveness of CHG washcloths 
for preventing surgical site infection [30]; it is unknown 
if this could be replicated in the ICU context. Studies 
have hypothesised that CHG washcloth bathing is 
potentially cost-effective through prevention of CLABSI 
and that nurses preferred this method over non-wash-
cloth bathing [31-33].
An important concern raised regarding application 
of antiseptics is the potential selection of antiseptic-
resistant pathogens, which should be monitored when 
introducing universal decolonisation strategies [34]. 
Only one study measured CHG MIC values between 
treatment arms, but reflected that the overall increase 
in resistance in the chlorhexidine group could repre-
sent a reduction in isolates that are inhibited by very 
low CHG concentrations [23].
Conclusion
This meta-analysis provides evidence that the use of 
CHG washcloths prevents HABSI in ICUs. The impact of 
CHG washcloth bathing appeared to be primarily due to 
its prevention of CLABSI. This effect was beneficial and 
comparable for CLABSI in all four studies. The reduc-
tion was possibly due to the reduction of commensal 
Gram-positive skin microorganisms. However, since 
the rate reduction was primarily due to Gram-positive 
bacteria, the possibility still remains that the inter-
vention effect is partially explained by a reduction in 
blood culture contamination. Hospitals with high base-
line hygienic standards of care and lower CLABSI rates 
may benefit less from CHG washcloth bathing; rather, 
the intervention can work as a ‘safety net’ when basic 
hygienic preventive measures are breached. Further 
research should apply separate classifications of pri-
mary, secondary and central line-associated HABSI 
types, should report catheter cultures to diagnose 
bloodstream infections to increase certainty and lower 
the risk of bias due to improper attribution of blood 
culture contaminants, should report baseline hygienic 
standard of care practices and should attempt to meas-
ure compliance with the daily CHG washcloth bathing 
intervention. A cost-effectiveness analysis can assess 
the added benefit of CHG washcloth bathing, taking 
into account differing standards of care.
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